GlassScriptPhysician profile
Morgen Shaff
NPI 1396873105
$3,986.00
in general payments reported to CMS, 2019-2025
29 companies · $509 in 2025
The $509 reported for 2025 was more than what 80% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $1,348 · 2023: $867 · 2024: $557 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.08 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $626.82 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.77 | 2021-2025 | Relistor |
| Ipsen Biopharmaceuticals, INC | $306.06 | 2021-2025 | Dysport |
| Boston Scientific Corporation | $249.54 | 2022-2024 | Wavewriter Alpha Prime 16, Infinion 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $224.76 | 2022 | |
| Amgen INC. | $206.57 | 2021-2022 | |
| Nevro Corp. | $190.39 | 2022-2023 | Senza |
| Scilex Pharmaceuticals INC. | $153.15 | 2021-2023 | Ztlido |
| Merz Pharmaceuticals, LLC | $106.59 | 2021-2022 | |
| Bioventus LLC | $101.09 | 2021-2025 | Gelsyn-3 |
| Grt US Holding, INC. | $92.65 | 2022 | |
| Saluda Medical Americas, INC. | $73.70 | 2024-2025 | Evoke |
| Spr Therapeutics, INC | $67.67 | 2022-2024 | Sprint Pns System |
| Uswm, LLC | $51.34 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $50.41 | 2025 | Symbravo |
| Almatica Pharma LLC | $49.58 | 2021 | |
| Idorsia Pharmaceuticals US INC | $42.62 | 2022-2024 | Quviviq |
| Redhill Biopharma INC. | $39.83 | 2021-2023 | |
| Vertex Pharmaceuticals Incorporated | $35.28 | 2025 | |
| Zimmer Biomet Holdings, INC. | $23.82 | 2024 | Gps III Platelet Concentration System |
| Medline Industries LP | $20.75 | 2024 | |
| Allergan, INC. | $20.74 | 2022 | |
| Averitas Pharma INC. | $20.73 | 2023 | Qutenza |
| Biodelivery Sciences International, INC. | $18.14 | 2021 | |
| Depuy Synthes Sales INC. | $16.76 | 2023 | Orthovisc, Monovisc |
| Arbor Pharmaceuticals, INC. | $15.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.43 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgen Shaff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.